MetaVia Inc. (MTVA)

MetaVia Inc. (MTVA) Healthcare & Pipeline Overview

MetaVia Inc., a clinical-stage biotechnology firm, targets cardiometabolic diseases with novel pharmaceuticals like DA-1241 for MASH and DA-1726 for obesity. The company focuses on standalone and combination therapies, positioning itself in the competitive biotechnology landscape with strategic partnerships and a pipeline of clinical and preclinical assets.

What Is the Investment Thesis for MTVA?

MetaVia Inc. presents a notable research candidate within the biotechnology sector, driven by its focused pipeline targeting high-prevalence cardiometabolic diseases. The Phase 2a clinical trial of DA-1241 for MASH represents a near-term value driver, with potential for positive data readout in the next 12-18 months. The preclinical development of DA-1726 for obesity offers longer-term growth potential, aligning with the expanding market for obesity therapeutics. The company's strategic partnerships, including the license agreement with Pfizer for Gemcabene, provide validation and potential revenue streams. However, the company's small market capitalization and limited cash runway represent significant risks. Successful clinical trial outcomes and securing additional funding are critical for MetaVia's continued growth and value creation.

Based on FMP financials and quantitative analysis

MTVA Key Highlights

• DA-1241 is in Phase 2a clinical trial for MASH, a liver disease with a high unmet medical need.
• DA-1726 is in preclinical development for obesity, a rapidly growing market.
• MetaVia has a license agreement with Pfizer for Gemcabene, providing potential revenue and validation.
• The company has a small team of 9 employees, indicating a lean operating structure.
• MetaVia's pipeline includes multiple therapeutic programs targeting various cardiometabolic diseases.

Who Are MTVA's Competitors?

MTVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MTVA's Key Strengths?

• Novel drug candidates targeting high-prevalence diseases.
• Clinical-stage pipeline with near-term value drivers.
• Strategic partnerships with established pharmaceutical companies.
• Experienced management team with expertise in drug development.

What Are MTVA's Weaknesses?

• Limited financial resources and short cash runway.
• Small team size and limited infrastructure.
• High reliance on clinical trial success.
• Competition from larger pharmaceutical companies.

What Could Drive MTVA Stock Higher?

• Data readout from the Phase 2a clinical trial of DA-1241 for MASH.
• Initiation of clinical trials for DA-1726 in obesity.
• Potential for new partnerships or licensing agreements.
• Advancement of other therapeutic programs in the pipeline.

What Are the Key Risks for MTVA?

• Financial-distress signal — its Altman Z-Score of -16.75 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for DA-1241 and DA-1726.
• Regulatory hurdles and approval delays.
• Competition from larger pharmaceutical companies.
• Limited financial resources and short cash runway.
• Inability to secure additional funding.

What Are the Growth Opportunities for MTVA?

• Expansion of DA-1241 into Combination Therapies: MetaVia has the opportunity to explore DA-1241 as a combination therapy for MASH. The MASH market is expected to grow significantly, reaching an estimated $25-$35 billion by 2030. Combination therapies could offer improved efficacy and address the complex pathophysiology of MASH, providing a competitive advantage for MetaVia. This strategy could unlock additional value and market share as the MASH treatment landscape evolves.
• Advancement of DA-1726 for Obesity Treatment: The obesity market is experiencing rapid growth, driven by increasing prevalence and awareness. MetaVia's DA-1726, a GLP-1 receptor and glucagon receptor dual agonist, has the potential to be a highly effective treatment option. The global obesity market is projected to reach over $40 billion by 2030. Successful preclinical and clinical development of DA-1726 could position MetaVia as a key player in this expanding market.
• Out-Licensing or Partnering of Additional Pipeline Assets: MetaVia's pipeline includes several other therapeutic programs, such as ANA001 for COVID-19, NB-01 for painful diabetic neuropathy, and NB-02 for cognitive impairment. Out-licensing or partnering these assets could generate non-dilutive funding and allow MetaVia to focus its resources on its core programs. This strategy could also provide validation for the company's technology platform and development capabilities.
• Expansion into New Therapeutic Areas within Cardiometabolic Diseases: MetaVia could leverage its expertise in cardiometabolic diseases to expand into new therapeutic areas, such as cardiovascular disease or kidney disease. These areas share common underlying mechanisms and risk factors with MASH, obesity, and diabetes. This expansion could diversify MetaVia's pipeline and reduce its reliance on a single therapeutic area, mitigating risk and creating new growth opportunities.
• Strategic Acquisitions or Mergers to Expand Capabilities and Pipeline: MetaVia could pursue strategic acquisitions or mergers to expand its capabilities, pipeline, and market reach. This could involve acquiring companies with complementary technologies, therapeutic programs, or expertise. Such transactions could accelerate MetaVia's growth and create synergies that enhance its competitive position. However, careful due diligence and integration are essential for successful acquisitions.

What Opportunities Does MTVA Have?

• Positive clinical trial results for DA-1241 and DA-1726.
• Expansion into new therapeutic areas within cardiometabolic diseases.
• Out-licensing or partnering of additional pipeline assets.
• Strategic acquisitions or mergers to expand capabilities.

What Threats Does MTVA Face?

• Clinical trial failures or delays.
• Regulatory hurdles and approval delays.
• Competition from new and existing therapies.
• Inability to secure additional funding.

What Are MTVA's Competitive Advantages?

• Proprietary drug candidates with novel mechanisms of action.
• Clinical-stage pipeline with potential for significant value creation.
• Strategic partnerships with established pharmaceutical companies.
• Expertise in cardiometabolic disease drug development.

What Does MTVA Do?

MetaVia Inc., formerly known as NeuroBo Pharmaceuticals, Inc., was rebranded in November 2024 to reflect its refined focus on cardiometabolic diseases. The company is dedicated to the development and commercialization of innovative pharmaceutical products aimed at addressing significant unmet medical needs in this therapeutic area. MetaVia's lead product candidate is DA-1241, a novel G-Protein-Coupled Receptor 119 agonist currently in Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). DA-1241 holds promise as both a standalone treatment and a potential combination therapy. Another key asset is DA-1726, an oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. Beyond these core programs, MetaVia is also advancing other therapeutic candidates, including ANA001, an oral niclosamide formulation for moderate COVID-19; NB-01 for painful diabetic neuropathy; NB-02 for cognitive impairment; and Gemcabene for dyslipidemia. The company has established strategic collaborations to support its development efforts, including a license agreement with Pfizer Inc. for Gemcabene and a joint research agreement with Dong-A ST and ImmunoForge for DA-1726. Headquartered in Cambridge, Massachusetts, MetaVia operates with a lean team of 9 employees under the leadership of CEO Hyung Heon Kim.

What Products and Services Does MTVA Offer?

• Develop novel pharmaceuticals for cardiometabolic diseases.
• Focus on treatments for MASH, obesity, and type 2 diabetes.
• Advance DA-1241, a G-Protein-Coupled Receptor 119 agonist, through clinical trials.
• Develop DA-1726, an oxyntomodulin analogue, for obesity treatment.
• Pursue strategic partnerships for research, development, and commercialization.
• Advance other therapeutic programs, including ANA001, NB-01, NB-02, and Gemcabene.

How Does MTVA Make Money?

• Develop and commercialize proprietary pharmaceutical products.
• Generate revenue through licensing agreements and partnerships.
• Potentially generate revenue through direct sales of approved products.
• Focus on high-value therapeutic areas with unmet medical needs.

What Industry Does MTVA Operate In?

The biotechnology industry is characterized by high-risk, high-reward ventures focused on developing innovative therapies for unmet medical needs. The cardiometabolic disease market, including MASH, obesity, and diabetes, is experiencing significant growth due to increasing prevalence and limited treatment options. MetaVia Inc. operates in this competitive landscape, facing competition from both large pharmaceutical companies and smaller biotech firms. The company's success depends on its ability to successfully navigate the regulatory approval process, secure funding, and differentiate its products in the market. The global MASH market is projected to reach billions of dollars in the coming years, presenting a significant opportunity for MetaVia.

Who Are MTVA's Key Customers?

• Patients with cardiometabolic diseases, such as MASH, obesity, and type 2 diabetes.
• Healthcare providers who prescribe and administer MetaVia's products.
• Pharmaceutical companies that may license or partner with MetaVia.
• Payers, including insurance companies and government healthcare programs.

How MetaVia Inc. Is Valued

MetaVia Inc. carries a market capitalization of $3.35M, placing it in the micro-cap category. Relative to its peer group, MTVA's quantitative score of 29/100 is below the peer average of 80/100.

Key Financial Metrics

Return on assets is -91.2%, showing how much profit it generates from its asset base. A current ratio of 2.73 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -187.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

MetaVia Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.75 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project MetaVia Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.49.

MTVA Financials

MTVA Latest News

MTVA Analyst Consensus

MTVA MoonshotScore

Latest MetaVia Inc. Analysis

Common Questions About MTVA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources